Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

• Masanobu Takahashi,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Keigo Komine,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Hiroo Imai,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Yoshinari Okada,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Ken Saijo,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Masahiro Takahashi,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Hidekazu Shirota,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Hisatsugu Ohori,

  Affiliation Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Shin Takahashi,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Natsuko Chiba,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Cancer Biology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Takahiro Mori,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Hideki Shimodaira,

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  ⨯
• Chikashi Ishioka

  * E-mail: chikashi@tohoku.ac.jp

  Affiliations Department of Medical Oncology, Tohoku University Hospital, Aoba-ku, Sendai, Miyagi, Japan, Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan

  http://orcid.org/0000-0002-3023-1227

  ⨯